Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 2/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HBB | P68871 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 5/20 | 0.37 |
| ▸ | NOS3 | P29474 | 4/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11986214 | 0.79 | NQO1 (0.41) | NQO1TSHRHBBHSD17B10L3MBTL1 | |
| SCHEMBL18564070 | 0.77 | POLB (0.52) | NQO2F2POLBMPOBACE1 | |
| SCHEMBL11986212 | 0.76 | NQO1 (0.44) | NQO2NQO1TSHRHBBHSD17B10 | |
| SCHEMBL8745764 | 0.75 | NQO1 (0.42) | NQO1POLB | |
| SCHEMBL15448467 | 0.74 | NQO2 (0.47) | NQO2F2TSHRHSD17B10POLB | |
| SCHEMBL15448466 | 0.74 | POLB (0.49) | NQO2F2HSD17B10POLBMPO | |
| SCHEMBL27185303 | 0.72 | F2 (0.47) | NQO2F2HSD17B10POLBNOS1 | |
| SCHEMBL11986218 | 0.72 | NQO1 (0.41) | NQO1TSHRHBBHSD17B10L3MBTL1 | |
| SCHEMBL11986229 | 0.72 | NQO1 (0.41) | NQO1TSHRHBBHSD17B10L3MBTL1 | |
| SCHEMBL23619822 | 0.71 | CYP1A2 (0.51) | NQO2F2TSHRHBBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2025-03-13 | — | — | US | disclosed |
| CN-118488952-A | Substituted quinoline derivatives | 安斯泰来制药有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023127814-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084062-A1 | SUBSTITUTED QUINOLINE DERIVATIVE | CHRNA4, CHRNA2, CHRNA5 | NQO2 54/4885NQO1 416/4885F2 4783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.